Floatz logo

Daunorubicin

Non-small Cell Lung Cancer, Squamous

PfizerPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Non-small Cell Lung Cancer, Squamous cohort.

Asset / SponsorPhaseRating
Fludarabine
Pfizer
Phase 2B
ETOPOSIDE
Pfizer
Phase 2CCC
Cytosin-Arabinosid
Pfizer
Phase 2CCC
Calaspargase Pegol
Pfizer
Phase 2CCC
Ladiratuzumab Vedotin
Seagen Inc.
Phase 2CCC
PEGASPARGASE
Pfizer
Phase 2CCC
pf-08634404
Pfizer
Phase 2CCC

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →